Related Experiment Videos
Essential role for Ras signaling in glioblastoma maintenance
Sheri L Holmen1, Bart O Williams
1Molecular Medicine and Virology Group, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA. sheri.holmen@vai.org
Cancer Research
|September 17, 2005
Summary
Continued KRas signaling is essential for maintaining malignant gliomas in vivo. Inhibiting KRas triggers tumor regression and extends survival, while reintroducing KRas restarts tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant gliomas are aggressive brain tumors often driven by oncogenic signaling pathways.
- Understanding the specific dependencies of these tumors is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the role of KRas signaling in the maintenance of malignant gliomas in a mouse model.
- To determine if KRas is a viable therapeutic target for glioma treatment.
Main Methods:
- Genetically engineered mice expressing activated KRas and Akt in glial progenitor cells to induce gliomas.
- Utilized a viral vector for inducible KRas expression to control signaling post-tumorigenesis.
- Compared tumor-free survival and tumor regression rates between groups with continuous and suppressed KRas expression.
Main Results:
- KRas signaling is indispensable for the in vivo maintenance of established malignant gliomas.
- Suppression of KRas led to significant tumor regression through apoptosis and increased animal survival.
- Re-expression of KRas in surviving cells reinitiated tumor growth, demonstrating retained tumorigenic potential.
Conclusions:
- KRas signaling is a critical dependency for malignant glioma maintenance.
- Targeting KRas offers a promising therapeutic strategy for glioma treatment, inducing regression and improving survival.
- A subset of glial progenitor cells can survive KRas inhibition and retain the capacity for tumor regrowth.